Crucell N.V.
Below you will find information from the register publication of inside information. The information has been provided by the organisation.
Registration date
06 apr 2010 - 07:43
Statutory name
Crucell N.V.
Title
Crucell Announces Collaboration with GlaxoSmithKline Biologicals on Second Generation Malaria Vaccine Candidate
Comments
Leiden, the Netherlands (April 6, 2010) – Dutch biopharmaceutical company Crucell N.V. (NYSE Euronext, NASDAQ: CRXL; Swiss Exchange: CRX) today announced that it has signed a binding letter of agreement with GlaxoSmithKline Biologicals (GSK) to collaborate on developing a second generation malaria vaccine candidate. Pre-clinical data from earlier studies indicated significantly enhanced immune responses against the malaria parasite (circumsporozoite stage of the Plasmodium falciparum) when Crucell’s Adenovirus (AdVac®) technology and GSK’s RTS,S/AS technology are used in combination, versus either component alone.
Date last update: 17 June 2026